In preclinical studies on TMD-8 lymphoma cells expressed wild-type BTK as well as L528W, C481S and T474I mutants, BGB-16673 demonstrated potent antiproliferative activity, even superior to covalent/non-covalent BTK inhibitors. This evidence concerns the gene BTK and lymphoma.